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Abstract
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Amylin is a pancreatic β-cell hormone co-secreted with insulin, plays a role in normal glucose
homeostasis, and forms amyloid in the pancreatic islets of individuals with type-2 diabetes.
Aggregated amylin is also found in blood and extra-pancreatic tissues, including myocardium.
Myocardial amylin accumulation is associated with myocyte Ca2+ dysregulation in diabetic rats
expressing human amylin. Whether deposition of amylin in the heart is a consequence of or a
contributor to diabetic cardiomyopathy remains unknown. We used amylin knockout (AKO) mice
intravenously infused with either human amylin (i.e, the aggregated form) or non-amyloidogenic
(i.e., monomeric) rodent amylin to test the hypothesis that aggregated amylin accumulates in the
heart in the absence of diabetes. AKO mice infused with human, but not rodent amylin, showed
amylin deposits in the myocardium. Cardiac amylin level was larger in males compared to
females. Sarcolemmal Ca2+ leak and Ca2+ transients were increased in myocytes isolated from
males infused with human amylin while no significant changes occurred in either females injected
with human amylin or in rat amylin-infused mice. In isolated cardiac myocytes, the amylin
receptor antagonist AC-187 did not effectively block the interaction of amylin with the
sarcolemma. In conclusion, circulating aggregated amylin accumulates preferentially in male vs.
female hearts and its effects on myocyte Ca2+ cycling do not require diabetic remodeling of the
myocardium.
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1. Introduction
Type-2 diabetes and insulin resistance are metabolic abnormalities that drive heart failure via
multiple mechanisms [1–5]. To compensate for insulin resistance, pancreatic β-cells increase
insulin secretion (hyperinsulinemia) [6]. Amylin is a ~4 kDa peptide hormone synthesized
and co-secreted with insulin by pancreatic β-cells [7, 8]. Prior studies showed that amylin
modulates ingestive behavior [9] and reduces insulin secretion [10–12] and sensitivity [13–
16]. Conversely, amylin gene deletion improved glucose tolerance in mice [17] suggesting
that amylin plays a role in energy homeostasis.

Author Manuscript

Amylin from humans aggregates, forming amyloid when overexpressed [8, 18, 19].
Aggregated amylin was shown to cause oxidative stress [20, 21], inflammation [22–24] and
apoptosis [18, 25] in the pancreas. In contrast, amylin from species that do not develop
type-2 diabetes spontaneously (i.e. mice and rats) has a different amino acid structure and a
reduced propensity to form amyloid [26]. Pharmacological induction of insulin resistance in
mice expressing human amylin caused amylin amyloid deposition, β-cell apoptosis and
overt hyperglycemia [27]. These pathologic changes were replicated in rodents
overexpressing human [25, 28], but not murine amylin [29]. Thus, hyperamylinemia, is an
early contributor to type-2 diabetes.
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Accumulating evidence (including our work [30–35]) demonstrates the presence of abundant
deposits of aggregated amylin in failing hearts [30–32] from patients with type-2 diabetes or
obesity, in brains [33–38] of patients suffering from Alzheimer’s disease and in kidneys [39]
of patients with type-2 diabetes. The source of amylin deposition in the heart (and brain and
kidneys) originates in the pancreas, as no amylin mRNA was found in cardiac [31] and brain
[35] tissues. Rats expressing human amylin in the pancreatic β-cells (HIP rats) accumulate
aggregated amylin in the pancreas [29], heart [30], brain [34, 40] and kidneys [41], similar
to humans with type-2 diabetes [30–39]. HIP rats develop type-2 diabetes [29] and heart
dysfunction characterized by diastolic dysfunction [30], cardiac hypertrophy [30, 31] and
dilation [31]. At the myocyte level, we found increased cytosolic Ca2+ and sarcolemmal
Ca2+ leak in HIP rats, but not in glucose- and age-matched diabetic rats that express
endogenous rat amylin [30]. We also reported that mitigating myocardial accumulation of
amylin improves myocyte Ca2+ handling and heart function in diabetic HIP rats [31].
However, it is unclear whether cardiac accumulation of amylin is promoted by diabetic
remodeling of the heart or would arise independent of such remodeling.
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In HIP rat hearts, we found that aggregated amylin accumulates both interstitially [32] and
inside myocytes [31, 32]. A potential venue for the amylin uptake in cardiac myocytes may
involve binding of amylin monomers to calcitonin gene-related peptide (CGRP) receptors.
CGRP receptors appear to play a role in internalization of monomeric amylin in pancreatic
β-cells [43] and neurons [44] and they are expressed in cardiac myocytes [42]. Alternatively,
cardiac amylin accumulation may result from deposition of aggregated amylin circulating in
the blood. This mechanism is consistent with our previously published data [32] showing
that amylin aggregates detected in cardiac myocytes, pancreas and blood all have similar
molecular weights.
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Here, we tested the hypothesis that the cardiac buildup of amylin and its subsequent effects
on myocyte function are independent of diabetes-mediated remodeling of the myocardium.
To test this hypothesis, we measured cardiac amylin accumulation and myocyte Ca2+
cycling in amylin knockout (AKO) mice intravenously infused with either aggregated human
amylin or non-amyloidogenic rat amylin. The reason for using AKO mice, not simply WT
mice, for this study, is twofold. First, it eliminates the potential confound factor that rodent
amylin and human amylin may form mixed oligomers. Second, comparing myocytes from
WT vs. AKO mice will clarify whether lack of amylin affects myocyte Ca2+ cycling. Of
note, previous investigations [17] demonstrated increased insulin secretion and improved
glucose tolerance in AKO mice compared to WT littermates. Blood glucose elimination was
enhanced in female compared to male AKO mice. Thus, lack of amylin appears to improve
insulin secretion and glucose homeostasis in mice. Using isolated cardiac myocytes, we also
investigated the efficacy of the CGRP receptor antagonist AC-187 to prevent the myocyte
amylin uptake and downstream cytotoxicity. Our findings may contribute to the
understanding of the complex molecular mechanisms underlying diabetic cardiomyopathy.

2. Materials and methods
2.1. Experimental animals
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Animal studies conform to the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was
approved by the Institutional Animal Care and Use Committees at University of Kentucky.
Frozen embryos of amylin knockout mice (AKO mice; line B6.129P2-Iapptm1Sgm/Kctt)
were purchased from EMMA (https://www.infrafrontier.eu/) and re-derived at Jackson
Laboratory. Genotyping was performed as described in Ref [17]. A total of 55 AKO mice
were used in the study (n=32 males and n=23 females), at an age of 8–9 months. AKO mice
were infused with either aggregated human amylin (n=9 for each sex) or non-amyloidogenic
rat amylin (n=5 per group/per sex) and used for measurements of myocyte amylin
deposition, Ca2+ transients and sarcolemmal Ca2+ leak. N=9 AKO mice of both sexes were
used as controls. Additionally, n=9 male AKO mice were used for assessing amylin
accumulation in the myocardial tissue upon infusion of human or rat amylin (vs. control; 3
mice per group). WT littermate mice (n=4 males and n=4 females) were used to measure the
baseline Ca2+ transient amplitude in cardiac myocytes and plasma interleukin (IL)-1β.
Metabolic characterization of AKO vs. WT mice was previously published [17].
Intravenous infusion of amylin
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AKO mice were intravenously infused, via the tail vein, with either aggregated human
amylin (2 µg/g body weight; AS-60804, AnaSpec, CA) or rat amylin (2 µg/g body weight;
74-5-10, American Peptide, CA) for 7 days (q.d.). For inducing aggregation, human was
dissolved in PBS (pH 7.4) at a concentration of 50 µM and maintained at 37°C for 72 hours
with occasional shaking [34]. Our previous data [34] show that blood from AKO rats infused
with human amylin under similar conditions (2 µg/g body weight, q.d., 7 days) has
comparable distributions of amylin-positive molecular complexes with blood from HIP rats
and humans with type-2 diabetes.
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The experimental protocol was previously [30, 31] described. Briefly, mice were
anesthetized by isoflurane (4.0%). When deep anesthesia was reached, hearts were excised
quickly, placed on a Langendorff perfusion apparatus and perfused with buffer containing 1
mg/ml collagenase. When the heart became flaccid, the left ventricular tissue was cut into
small pieces, dispersed, filtered and kept in a standard Tyrode’s solution containing (in
mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 10 glucose, 5 HEPES, and 1 CaCl2 (pH=7.4). All
experiments were performed at room temperature.
Amylin accumulation in cardiac myocytes
Isolated cardiac myocytes were lysed as described before [32] and amylin content was
assessed by ELISA (EIA-AM, Raybiotech, GA) according with manufacturer’s protocol.
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Immunofluorescence
Immunofluorescence was used in myocardial tissue and isolated myocytes from AKO mice
infused with aggregated human amylin and control AKO mice (no amylin infusion). The
primary antibodies were anti-human amylin antibody (1:200, SC-377530, Santa Cruz, TX;
raised in rabbit) and CGRP antibody (ab47027, abcam, Cambridge, MA; raised in rabbit).
The secondary antibody were Alexa Fluor 568 conjugated anti-rabbit IgG (A11036,
Invitrogen, MA) and Texas red conjugated anti-rabbit IgG (SC-2780; Santa Cruz; TX).
Ca2+ transient measurements
Ca2+ transients were measured in isolated myocytes loaded with Fluo-4 (10 µM for 20 min)
and electrically stimulated at 0.2, 0.5, 1 and 2 Hz.
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Sarcolemmal Ca2+ leak
To measure the passive Ca2+ leak across sarcolemma, myocytes were loaded with Fura-2 (10
µM for 25 min) and pre-incubated (10 min) with 10 µM thapsigargin to block SERCA and
empty the SR of Ca2+. Sarcolemmal Ca2+ leak was then measured the initial rate of [Ca2+]i
decline upon reducing [Ca2+]o from 1 mM to 0, with the Na+/Ca2+ exchanger blocked by
using a 0Na+/0Ca2+ external solution (Na+ was replaced by Li+, CaCl2 was omitted and 10
mM EGTA added to the Tyrode’s solution) and the plasma membrane Ca2+ ATPase
inhibited with carboxyeosin (20 µM), as before [30].
IL-1β measurement
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Plasma IL-1β was measured by ELISA (RAB0277, Sigma, MO, US) according with
manufacturer’s protocol.
Statistical analysis
Comparison of two groups was done using unpaired Student’s t-test. One-way analysis of
variance with Bonferroni’s post hoc test was used to compare multiple groups. Data are
presented as means ± SEM. Difference between groups was considered significant when P <
0.05. All analyses were performed using GraphPad Prism 5.0 software.
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3. Results
3.1. Lack of basal amylin has no effect on myocyte Ca2+ cycling
We have previously [30] shown that incubation of isolated cardiac myocytes with human
amylin (50 µM; 2 hour incubation time) results in a significant increase of the Ca2+ transient
amplitude [30]. A modest increase of Ca2+ transient amplitude was also measured in cardiac
myocytes incubated with rat amylin 50 µM; 2 hour incubation time). To test whether lack of
basal amylin expression alters myocyte Ca2+ handling, we compared Ca2+ transients in
cardiac myocytes isolated from WT and AKO mice (both males and females; Fig 1). Our
results (Fig 1) showed similar amplitude and decline time for Ca2+ transients in myocytes
from WT and AKO mice. So, the presence of endogenous mouse amylin had no effect on
basal myocyte Ca2+ cycling.

Author Manuscript

3.2. Circulating aggregated amylin accumulates in the myocardium in absence of diabetes
Male and female AKO mice were intravenously infused with either aggregated human
amylin or non-amyloidogenic (i.e, monomeric) rat amylin (2 µg/g body weight) for 7 days
(q.d.), as described in Methods. Mice were then euthanized for cardiac myocyte isolation.
The level of amylin present in myocyte lysates from AKO mice infused with aggregated
human amylin (h-Amy) or rodent amylin (r-Amy) were measured by ELISA (Fig 2A).
Myocytes from males injected with aggregated human amylin show significant accumulation
(P=0.02, One-sample t-test to compare the mean to zero) whereas no amylin was found in
myocytes from females injected with human amylin (P=0.45). Infusion of rat amylin
resulted in no significant myocardial amylin accumulation in either male (P=0.96) or female
(P=0.64) mice.
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The presence of amylin in myocyte lysates from male AKO mice infused with aggregated
human amylin indicates that amylin attached to the sarcolemma and/or incorporated into
cardiac myocytes. To further test the attachment of circulating aggregated amylin to the
sarcolemma from, we labeled isolated myocytes with an anti-amylin antibody and
performed immunofluorescence (Fig 2B). Myocytes from human amylin-infused AKO male
mice showed a strong immunofluorescence signal at the sarcolemma, consistent with the
ELISA results in Fig 2A.
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Fig 2C–E displays the results of immunofluorescent staining of amylin (green) in
myocardial sections from AKO mice with or without amylin injection. Myocardial tissue
from male AKO mice infused with aggregated human amylin showed a robust amylin
immunofluorescence signal within the interstitial spaces or/and at the sarcolemma (Fig 2C).
In contrast, immunofluorescence staining of myocardial tissues from male AKO mice
infused with rodent amylin (Fig 2D) is similar to that in controls (AKO mice with no amylin
infusion; Fig 2E), indicating the lack of amylin deposition in myocardium. In these
experiments, HIP rat pancreatic tissue served as positive control for amylin deposition (Fig
2F).
Thus, acute intravenous infusion of aggregated human amylin (but not rodent amylin)
caused myocardial amylin deposition and attachment to the sarcolemma in male AKO mice.
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Present results are consistent with our previous data from HIP rats [30–32] and isolated
cardiac myocytes incubated with exogenous human amylin [30, 32].
3.3. Myocardial amylin accumulation alters myocyte Ca2+ cycling
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Next, we tested whether circulating amylin affects myocyte Ca2+ cycling by measuring Ca2+
transients in myocytes from male and female AKO mice infused with either aggregated
human amylin or rat amylin versus control AKO mice (Fig 3). At all stimulation
frequencies, Ca2+ transient amplitude was significantly larger in myocytes from male AKO
mice infused with aggregated human amylin versus control AKO male (Fig 3A,C). In
contrast, infusion of rat amylin in male AKO mice induced no effect on myocyte Ca2+
cycling (Fig 3A,C), in agreement with the lack of myocardial amylin deposition in this
group (Fig 2A). Cardiac myocytes from AKO females infused with human or rat amylin,
which did not accumulate amylin (Fig 2A), showed no change in Ca2+ transient amplitudes
(Fig 3B,D). Neither human or rat amylin-infusion altered the decline of Ca2+ transients,
consistent with our prior data in isolated myocytes incubated with amylin [34]. Thus,
myocardial amylin accumulation is the cause for the larger Ca2+ transient amplitude in male
AKO mice infused with aggregated human amylin, consistent with our previous results from
HIP rats [30] and isolated cardiac myocytes incubated with exogenous human amylin [30].
3.4. Circulating aggregated amylin provokes sarcolemmal Ca2+ leak
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We hypothesized that myocardial amylin accumulation alters myocyte Ca2+ cycling by
increasing sarcolemmal Ca2+ permeability. To test this hypothesis, we measured the passive
sarcolemmal Ca2+ leak in myocytes from male AKO mice intravenously infused with
aggregated human amylin control AKO mice (no amylin infusion). Myocytes were preincubated with thapsigargin to inhibit SERCA and thus empty the sarcoplasmic reticulum of
Ca2+. Resting [Ca2+]i under these conditions was similar in myocytes from human amylininfused and control AKO males (Fura-2 ratio of 2.63±0.10 vs. 2.57±0.10). We then
measured the initial rate of [Ca2+]i decline upon reducing [Ca2+]0 from 1 to 0 mmol/L with
Na+/Ca+ exchanger, Ca2+ influx and plasma membrane Ca2+-ATPase blocked (Fig 4A).
Sarcolemmal Ca2+ leak was significantly larger in myocytes from human amylin-infused
rats compared to controls (Fig 4B).
3.5. Blocking CGRP receptors does not mitigate the amylin-mediated effects on myocytes,
ex vivo
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Previous work [42] suggested that amylin binds to the CGRP receptors on the sarcolemma.
We tested whether blocking CGRP receptors by the AC-187 inhibitor reduces the interaction
of amylin with cardiac myocytes, ex vivo. Immunoconfocal microscopy showed colocalization of amylin with CGRP receptors at the sarcolemma in cardiac myocytes
incubated with human amylin (100 nM for 6 h; Fig 5A). However, co-incubation of isolated
myocytes with the CGRP receptor AC-187 (100 nM) did not reduce the human amylinprovoked sarcolemmal Ca2+ leak (Fig 5B). In contrast the membrane sealant P188 prevented
the increase in sarcolemmal Ca2+ leak in myocytes incubated with aggregated amylin (Fig
5B), which is consistent with our previous data [32] indicating that P188 efficiently reduces
amylin-mediated peroxidative damage of the sarcolemma.
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3.6. Circulating aggregated amylin triggers systemic inflammation in male AKO mice
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Accumulation of aggregated amylin in cells and tissues (including the heart) triggers a
proinflammatory response [22–24, 32]. The plasma level of the proinflammatory cytokine
IL-1β was elevated in male AKO mice infused with aggregated amylin (Fig 6). This
systemic inflammatory response to aggregated amylin was not observed in female AKO
mice. Infusion of rat amylin had no effect on plasma IL-1β in AKO mice (Fig 6).

4. Discussion
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In summary, we found that intravenous infusion of aggregated human amylin leads to
amylin accumulation in the myocardium and an increase in sarcolemmal Ca2+ leak and Ca2+
transient amplitudes in healthy, non-diabetic AKO mice. Alteration of sarcolemmal Ca2+
fluxes by circulating aggregated amylin in AKO mice is consistent with our previously
published data [32] showing sarcolemmal peroxidative injury and cardiac inflammation in
normal WT mice infused with aggregated amylin. These results suggest the following: i) the
presence of amylin aggregates in hearts of humans with type-2 diabetes [30–32] is the result
of higher levels of circulating aggregated amylin in the pre-diabetic state (when the secretion
of insulin, and thus amylin, is greatly increased) rather than as a consequence of cardiac
diabetic remodeling or heart failure; ii) human hearts undergoing the amylin stress are likely
predisposed to a more rapid destabilization of sarcolemmal processes in diabetes.
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In contrast to human (amyloidogenic) amylin, intravenous injection of monomeric rat
amylin did not result in cardiac amylin deposition and had no effects on myocyte Ca2+
cycling. These results are consistent with previous studies [8, 18–22, 25–32] showing that
amylin accumulation in cells and tissues is promoted by the amyloidogenicity of human
amylin and increased propensity of aggregated amylin to incorporate in cellular membranes.
Myocardial amylin accumulation may also be explained by an impaired clearance of
aggregated amylin. Future studies need to investigate factors contributing to the impaired
clearance of circulating aggregated amylin in vivo.
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Blood glucose elimination is enhanced in female AKO mice compared to males [17]. We
found that aggregated human amylin incorporated only in hearts from males but not female
AKO mice, indicating a significant sex-dependent effect which might be estrogendependent. Indeed, we recently [34] showed that, compared to males, female HIP rats
developed hyperglycemia and neurologic deficits later in life (i.e., ~12 months vs. ~18
months of age). These results are consistent with previous data [45] indicating that
pancreatic amylin deposition is more abundant in men compared to women, which was
attributed to increased insulin resistance in men [46, 47]. Ovariectomy or employing older
female mice (as in our recent study in HIP rats [34]) might mitigate the sex difference in
amylin-induced pathology. Indeed, previous studies demonstrated sex differences in cardiac
myocyte ion channels [48–52], Ca2+ cycling [53, 54], contractions [53] and metabolism [55,
56], which may contribute to the differential effects of amylin stress. Elucidating sexspecific cardiac responses to amylin stress may help in understanding the development and
progression of heart failure in men vs. women suffering from diabetes.
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Previously published data showed that inducing diabetic states alters myocyte Ca2+ cycling
[1, 57–59] in rodents, even in the absence of cardiac amylin deposition. The proposed
mechanism for diabetes-induced Ca2+ dysregulation (see Fig 7; schematic mechanism)
involves activation of CaMKII due to O-linked glycosylation (magenta pathway) [60] and
oxidation (orange pathway) [61] of the kinase. CaMKII activation enhances sarcoplasmic
reticulum (SR) Ca2+ leak through phosphorylation of ryanodine receptors (RyRs).
Moreover, oxidative stress favors oxidation of the thiol residues of RyRs, which increases
the opening probability of the channels [62]. Thus, the induction of diabetic states in rodents
without cardiac amylin accumulation affects myocyte Ca2+ cycling mainly via the SR Ca2+
leak. Our results indicate that cardiac amylin accumulation alters myocyte Ca2+ cycling
through provoking sarcolemmal Ca2+ leak (Fig 7; brown pathway), an effect that does not
entail diabetic remodeling of myocardium. Our previous results [30, 31] showed that
myocyte Ca2+ dysregulation caused by the enhanced sarcolemmal Ca2+ leak activates Ca2+mediated transcriptional signaling leading to SERCA downregulation. Thus, amylin-induced
sarcolemmal Ca2+ leak appears as a new and complementary mechanism of cardiac Ca2+
dysregulation in diabetic cardiomyopathy. While our previous study [30] showed that
cardiac amylin accumulation is associated with diastolic dysfunction in HIP rats, the
functional in vivo consequences of the infusion of aggregated amylin in AKO mice have not
been explored, which is a limitation of the present work.
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In pancreatic β-cells [43] and neurons [44], binding of amylin to CGRP receptors is an
important mechanism of internalization of monomeric amylin. Blocking CGRP receptors
with the AC-187 inhibitor did not reduce amylin-mediated sarcolemmal Ca2+ leak in
isolated cardiac myocytes suggesting that other mechanisms contribute to amylin-mediated
myocyte Ca2+ dysregulation, i.e., sarcolemmal injury. Other possible explanations are that
the 100 nM amylin concentration overcomes the CGRP receptor blockade or/and a lower
selectivity of the AC-187 inhibitor for cardiac myocyte CGRP receptors compared to
neurons and β-cells.

5. Conclusions
Cardiac amylin accumulation and subsequent amylin-mediated effects on myocyte Ca2+
cycling result from circulating aggregated (human) amylin, but not monomeric (rat) amylin
and do not entail pre-existing diabetic remodeling of myocardium or heart failure. Lack of
basal amylin has no effect on cardiac contractility; however, circulating aggregated amylin
provokes myocyte Ca2+ mishandling by enhancing the sarcolemmal Ca2+ leak.
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Hyperamylinemia is common in prediabetes [6–8] and promotes amylin aggregation [8, 25,
30, 31]. Aggregated amylin was identified in the blood [32] and cardiac tissue [30] of
patients with type-2 diabetes or obesity. Present results demonstrate that circulating
aggregated amylin induces cardiotoxicity independent of diabetic remodeling of
myocardium. Thus, circulating aggregated amylin represents a potential therapeutic target in
diabetic cardiomyopathy.
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Highlights
•

Basal amylin has no effect on myocyte Ca2+ cycling.

•

Aggregated amylin provokes myocyte Ca2+ dysregulation by enhancing
sarcolemmal Ca2+ leak.

•

Myocyte uptake of amylin does not entail pre-existing diabetic remodeling of
myocardium.

•

Circulating aggregated amylin, but not monomeric amylin, accumulates in
myocardium.

•

Cardiac amylin accumulation is larger in male compared to female mice.
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Figure 1. Basal amylin has no effect on myocyte Ca2+ cycling
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(A–B) Representative recordings of Ca2+ transients triggered at 0.2, 0.5, 1 and 2 Hz in
cardiac myocytes from male (A) and female (B) WT and AKO mice. (C) Ca2+ transient
amplitudes in cardiac myocytes from male WT mice (10 cells, 4 mice) vs. male AKO mice
(11 myocytes, 4 mice). (D) Ca2+ transient amplitudes in cardiac myocytes from female WT
mice (11 cells, 4 mice) vs. female AKO mice (13 myocytes, 3 mice). (E-F). The decline time
of Ca2+ transients triggered by excitation at 0.5 Hz in myocytes from male (C) and female
(D) WT and AKO mice. In all groups, data were recorded from 2–3 myocytes/mouse and are
presented as the mean±SEM for myocytes.
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Figure 2. Circulating aggregated (human) amylin, but not monomeric (rat) amylin, promotes
myocardial amylin accumulation

Author Manuscript

(A). ELISA data showing the average levels of amylin present in cardiac myocyte lysates
from male and female AKO mice infused with either aggregated human amylin (h-Amy) or
rat amylin (r-Amy). Measurements were done in 9 males and 5 females for both h-Amy and
r-Amy. *P<0.05 using One-sample t-test to compare the mean to zero). (B).
Immunofluorescence staining of amylin in cardiac myocytes isolated from amylin infusedmale AKO mice vs. male AKO mice infused with rat amylin (r-Amy). (C–E).
Immunofluorescence staining of amylin in cardiac sections from amylin infused-male AKO
mice vs. control AKO mice (no amylin infusion). (F). Immunofluorescence staining of
amylin in pancreatic tissue from HIP rats (positive control for amylin staining).
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Figure 3. Circulating aggregated amylin increases myocyte Ca2+ transient amplitude
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(A–B) Ca2+ transients recorded in myocytes from control AKO mice, AKO mice that were
infused with aggregated human amylin (h-Amy) and AKO mice injected with monomeric rat
amylin (r-Amy). Panel (A) shows recording in myocytes from males and panel (B) shows
myocytes from females. (C) Mean Ca2+ transient amplitude in cardiac myocytes from male
AKO mice infused with either aggregated human amylin (24 cells, 6 mice) or rat amylin (35
myocytes from 6 mice), and control AKO males (15 cells, 3 mice). (D) Mean Ca2+ transient
amplitude in cardiac myocytes from female AKO mice infused with aggregated human
amylin (29 cells, 6 mice) or rat amylin (32 cells, 6 mice) and control AKO females (14 cells,
3 mice).
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Figure 4. Circulating aggregated amylin provokes sarcolemmal Ca2+ leak

(A) Representative examples of passive sarcolemmal Ca2+ leak measurements. (B) Mean
data for the sarcolemmal Ca2+ leak in cardiac myocytes from male AKO mice infused with
aggregated human amylin (h-Amy; 15 myocytes, 3 rats) and from male AKO mice with no
amylin infusion (control; 12 myocytes, 3 mice). * P<0.05, Student’s t-test
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Figure 5. Inhibition of CGRP receptors has no significant effect on the ex vivo attachment of
amylin to cardiac myocytes

(A) Dual immunofluorescence staining of amylin (green) and CGRP receptor (red) in
cardiac myocytes incubated ex vivo with human amylin (100 nM for 6 hours). (B) Passive
sarcolemmal Ca2+ leak in cardiac myocytes from male AKO mice co-incubated with human
amylin (100 nM) for 6 h and either the AC-187 inhibitor (100 nM) or the P188 membrane
sealant (100 nM). Cardiac myocytes from male AKO mice (no amylin) were used as
controls.For each group, measurements were done on ≥6 myocytes from 3 different mice.
*P<0.05.
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Figure 6. Circulating aggregated amylin triggers systemic inflammation in male AKO mice
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ELISA data showing the average levels of IL-1β in plasma from male and female AKO mice
infused with either aggregated human amylin (h-Amy) or rat amylin (r-Amy). Measurements
were done in 9 males and 5 females for both h-Amy and r-Amy. Plasma from WT littermate
mice (n=4 males and n=4 females) was used as control. *P<0.05 using One-sample t-test to
compare the mean to zero).
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Figure 7. Proposed mechanism for the additive effect of amylin-induced sarcolemmal Ca2+ leak
to myocyte Ca2+ dysregulation in diabetes

Diabetes-induced Ca2+ dysregulation involves activation of CaMKII due to O-linked
glycosylation (magenta pathway) [60] and oxidation (orange pathway) [61] of the kinase.
CaMKII activation enhances sarcoplasmic reticulum (SR) Ca2+ leak through
phosphorylation of ryanodine receptors (RyRs). Thus, the induction of diabetic states in
rodents without cardiac amylin accumulation affects myocyte Ca2+ cycling mainly via the
SR Ca2+ leak. Cardiac amylin accumulation alters myocyte Ca2+ cycling through provoking
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sarcolemmal Ca2+ leak (brown pathway), an effect that does not entail diabetic remodeling
of myocardium.
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